Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter

[1]  Yoshiyuki Suzuki,et al.  Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b , 2018, Journal of medical virology.

[2]  M. Kumar,et al.  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. , 2017, Journal of hepatology.

[3]  Atsushi Hokari,et al.  Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b , 2017, World journal of gastroenterology.

[4]  B. Seifert,et al.  Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[5]  D. Nan,et al.  Incidence and Risk Factors , 2015 .

[6]  V. Wong,et al.  Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis , 2014, Digestive Diseases and Sciences.

[7]  J. Pawlotsky,et al.  Animal models in the study of hepatitis C virus-associated liver pathologies , 2011, Expert review of gastroenterology & hepatology.

[8]  Robert V Farese,et al.  Efficient Hepatitis C Virus Particle Formation Requires Diacylglycerol Acyltransferase 1 (DGAT1) , 2010, Nature Medicine.

[9]  K. Koike,et al.  Lipid Metabolism and Liver Disease in Hepatitis C Viral Infection , 2010, Oncology.

[10]  R. Chung,et al.  Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long‐term follow‐up , 2009, Hepatology.

[11]  F. Negro,et al.  Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[12]  Alessandra Conversi,et al.  Comparative Analysis , 2009, Encyclopedia of Database Systems.

[13]  S. Milani,et al.  Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C , 2008, Gut.

[14]  F. Penin,et al.  Structural Determinants That Target the Hepatitis C Virus Core Protein to Lipid Droplets* , 2006, Journal of Biological Chemistry.

[15]  K. Koike.  Hepatitis C Virus Infection Can Present with Metabolic Disease by Inducing Insulin Resistance , 2005, Intervirology.

[16]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[17]  K. Koike,et al.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. , 2004, Gastroenterology.

[18]  R. Stravitz,et al.  Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome , 2003, American Journal of Gastroenterology.

[19]  K. Koike,et al.  Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[20]  D. Pessayre,et al.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[22]  V. Agnello,et al.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Kohara,et al.  Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates , 1999, Hepatology.

[24]  R. Thomssen,et al.  Low density lipoprotein receptor as a candidate receptor for hepatitis C virus , 1999, Journal of medical virology.

[25]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[26]  K Koike,et al.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.

[27]  M. Kohara,et al.  Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Schiff,et al.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1993, Gastroenterology.

[29]  F. Schaffner,et al.  The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis , 1992, Hepatology.

[30]  G. Reaven,et al.  Evidence for an independent relationship between insulin resistance and fasting plasma HDL‐cholesterol, triglyceride and insulin concentrations , 1992, Journal of internal medicine.

[31]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.